Edwyn

Tools

Edwyn Search companies, tickers, CIKs…⌘K

Loading stock comparison…

Workspace›Comparisons›

Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.

vs

On this page

Footer

Edwyn

Build private company valuation reports, benchmark startup comps, uncover intrinsic value, and analyze data sourced directly from the SEC EDGAR database.

Subscribe to our newsletter

Get the latest financial trends sent to your inbox.

Email address

Products

Stock Comparisons
Valuation Reports
EDGAR Database

Guides

What is Enterprise Value?
What is Intrinsic Value?
How much is my company worth?
Valuation practice quiz

Company

About
Investing Ideas
Contact us
Register

Legal

Privacy
Terms

© Edwyn, LLC. All rights reserved.

www.edwyn.app is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.edwyn.app represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Edwyn, LLC be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.edwyn.app, or relating to the use of, or inability to use, www.edwyn.app or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Edwyn

Contact us What is Enterprise Value?What is Intrinsic Value?

Tesla vs GM Apple vs Microsoft Nvidia vs AMD

Edwyn

Tools

Public Company Financials

Stock Comparison

Investing Ideas

Intrinsic Value Calculator

Private Valuation Reports

Tesla vs GM Apple vs Microsoft Nvidia vs AMD

GSK plc (GSK) vs. Fox Corp (FOXA) Stock Comparison & Valuation | Edwyn

Workspace›Comparisons›GSK vs FOXA

GSK vs FOXA: valuation and financial comparison

Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.

Coverage medium · 60%Data state: stale

Change companies

GSK plc

GSK

FY 2025 · View financials

—

Price unavailable

vs

vs

Fox Corp

FOXA

FY 2026 · View financials

Decision snapshot: GSK stock price vs FOXA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.

Fair value engine Smart diff Side-by-side financials Historical trends Enterprise value Intrinsic value (DCF)Solvency Relative positioning High-level analysis Related research More comparisons

On this page

Fair value engine Smart diff Side-by-side financials Historical trends Enterprise value Intrinsic value (DCF)Solvency Relative positioning High-level analysis Related research More comparisons

Data from SEC EDGAR. Prices delayed 15 min.

Quick read

Fair value engine

Each company valued on the other's multiple, then compared with the market price.

GSK · current price

—Price unavailable

Implied fair value · at FOXA's multiple

—

Needs FOXA P/E.

FOXA · current price

—Price unavailable

Implied fair value · at GSK's multiple

—

Needs GSK P/E.

Engine logicGSKvalued onFOXA’smultiple

Metric by metric

—

Price unavailable

Smart diff

Where each company leads, and how wide the gap is.

6 metrics shown

MetricGSKFOXALeads · spread

Revenue growth (YoY)

Growth lag

4.1%

5.1%

FOXA leads by 18.8%FOXA−18.8%

Gross margin

Pricing power

72.4%

N/M

Insufficient dataN/M—

EBITDA margin

Operating leverage

22.0%

18.1%

GSK leads by 21.6%GSK+21.6%

EV/Revenue

Lower is better

N/M

N/M

Insufficient dataN/M—

P/E

Not comparable

N/M

N/M

Not comparableN/M—

Net debt / EBITDA

Lower leverage

5.8

N/M

Insufficient dataN/M—

Statements

Side-by-side financials

Core statements aligned to each company's latest fiscal year.

Income statement · USDGSK · FY 2025FOXA · FY 2026Delta

Revenue$32.67B$17.13B90.7% higher

Gross profit$23.65B—N/A

Operating income——N/A

EBITDA$7.20B$3.10B132.0% higher

Net income$6.29B$1.73B264.2% higher

EPS2.83.826.5% lower

Revenue growth4.1%5.1%18.8% lower

Gross margin72.4%—N/A

Operating margin——N/A

EBITDA margin22.0%18.1%21.6% higher

Net margin19.3%10.1%90.9% higher

SEC periods: GSK FY 2025 (ended Dec 31, 2025) · FOXA FY 2026 (ended Jun 30, 2026). Fiscal years are not aligned.

Trendline

Historical trends

Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.

GSKFOXA

Price framework

Enterprise value

Market cap plus debt, less cash.

GSK plc

—

Market cap: —
Debt: +$44.87B
Cash: −$3.40B

Fox Corp

—

Market cap: —
Debt: +$7.21B
Cash: −$0.00

Price framework

Intrinsic value (DCF)

Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.

GSK plc · implied price per share

$5.80

$54.00B intrinsic value÷2.16B shares=$5.80

Bear

$4.93

Base

$5.80

Bull

$6.67

Profit base$7B

Growth10.0%

Discount rate12.0%

Horizon5y

Fox Corp · implied price per share

$14.58B

$21.79B intrinsic value÷1 shares=$14.58B

Bear

$12.40B

Base

$14.58B

Bull

$16.77B

Profit base$3B

Growth10.0%

Discount rate12.0%

Horizon5y

Balance sheet health

Solvency

Financial health checks to separate durable balance sheets from potential value traps.

Piotroski F-Score

Financial strength on a 0–9 scale.

4/ 9 · GSKModerate

5/ 9 · FOXAModerate

Altman Z-Score

Bankruptcy-risk signal from balance sheet and earnings power.

Not enough data to score either balance sheet.

Liquidity and leverageGSKFOXALeads

Debt / equity

Total debt against shareholders' equity

—

0.62x

Net debt / EBITDA

Leverage against operating earnings

5.76x

—

Cash and equivalents

Liquid reserves on the balance sheet

$3.40B

—

Total debt

Interest-bearing obligations outstanding

$44.87B

$7.21B

FOXA

Comparable set

Relative positioning

Where the pair sits against the wider comparable set.

AbbVie Inc.

GSK vs ABBV

Amgen Inc

GSK vs AMGN

Bristol Myers Squibb Co

GSK vs BMY

Johnson & Johnson

GSK vs JNJ

ELI LILLY & Co

GSK vs LLY

Keep comparing

More comparisons

Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.

PFIZER INC

GSK vs PFE

ELI LILLY & Co

GSK vs LLY

BRISTOL MYERS SQUIBB CO

GSK vs BMY

JOHNSON & JOHNSON

GSK vs JNJ

AbbVie Inc.

GSK vs ABBV

AMGEN INC

GSK vs AMGN

Sinclair, Inc.

GSK vs SBGI

TEGNA INC

GSK vs TGNA

COMCAST CORP

GSK vs CMCSA

Walt Disney Co

GSK vs DIS

Warner Bros. Discovery, Inc.

GSK vs WBD

Paramount Global

GSK vs PARA

$50.05-1.61%

Live quote

LLM-powered synthesis

High-level analysis

An on-demand narrative read of the same deterministic data.

AI synthesis is not available yet

The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.

1Deep interpretation of current valuation multiples
2Analysis of fundamental margins and balance sheet signals
3Key structural risks and actionable takeaways

$65.77-2.87%

Live quote